SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KBAL, DSEY, ADAP, TCRR

If you are a Kimball shareholder, click here to learn more about your rights and options .

Metadata
Provider: 
GlobeNewswire, Inc.GlobeNewswire, Inc.
Retrieved on: 
Thursday, March 9, 2023
Information
Tags: 
Diversey Holdings, Advertising, Fraud, Therapy, HNI, Kimball International, HNI Corporation, Sale, Diversey, Security (finance), Holding company, Solenis
Geotags: 
NEW YORK, NY, US, KIMBALL
⚠ partially generated by AI ↴
Organisation: 
HALPER SADEH, HALPER SADEH LLC, KIMBALL INTERNATIONAL, DIVERSEY, TCR2 THERAPEUTICS
Stock Symbol: 
NASDAQ:KBAL
NASDAQ:DSEY
NASDAQ:ADAP
NASDAQ:TCRR
Summary
Key Points: 
  • If you are a Kimball shareholder, click here to learn more about your rights and options .
  • If you are a Diversey shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.



NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Kimball International, Inc. (NASDAQ: KBAL)’s sale to HNI Corporation for $9.00 in cash and 0.1301 shares of HNI common stock for each share of Kimball common stock. If you are a Kimball shareholder, click here to learn more about your rights and options.

Diversey Holdings, Ltd. (NASDAQ: DSEY)’s sale to Solenis for $8.40 per share in cash. If you are a Diversey shareholder, click here to learn more about your rights and options.

Adaptimmune Therapeutics plc (NASDAQ: ADAP)’s merger with TCR² Therapeutics Inc. Under the terms of the agreement, TCR² stockholders will receive 1.5117 Adaptimmune ADS for each TCR² share. Following the closing of the transaction, Adaptimmune shareholders will own approximately 75% of the combined company. If you are a Adaptimmune shareholder, click here to learn more about your rights and options.

TCR² Therapeutics Inc. (NASDAQ: TCRR)’s sale to Adaptimmune Therapeutics plc for 1.5117 Adaptimmune ADS for each TCR² share is fair to TCR² shareholders. Following the closing of the transaction, TCR² stockholders will own approximately 25% of the combined company. If you are a TCR² shareholder, click here to learn more about your rights and options.

Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected].

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]  
https://www.halpersadeh.com


Primary Logo
Copyright: 
2023 GlobeNewswire, Inc.. All Rights Reserved.